NYSE:ANVS Annovis Bio Q4 2025 Earnings Report $1.66 -0.10 (-5.43%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.68 +0.03 (+1.81%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Annovis Bio EPS ResultsActual EPS-$0.39Consensus EPS -$0.31Beat/MissMissed by -$0.08One Year Ago EPSN/AAnnovis Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnnovis Bio Announcement DetailsQuarterQ4 2025Date3/13/2026TimeBefore Market OpensConference Call DateMonday, March 16, 2026Conference Call Time7:00AM ETUpcoming EarningsAnnovis Bio's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Annovis Bio Earnings HeadlinesBrokerages Set Annovis Bio, Inc. (NYSE:ANVS) Price Target at $13.50July 14, 2026 | americanbankingnews.comAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s DiseaseJuly 7, 2026 | markets.businessinsider.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 25 at 1:00 AM | Altimetry (Ad)Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's DiseaseJuly 7, 2026 | globenewswire.comAnnovis Bio Inc.: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific OfficerJuly 1, 2026 | finanznachrichten.deAnnovis Appoints Cheng Fang, Ph.D., as Chief Scientific OfficerJuly 1, 2026 | globenewswire.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS) (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions. The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients. Preclinical studies suggest that this mechanism may also have applications in mitigating neuroinflammation. In addition to ANVS401, Annovis is advancing a second-generation program, ANVS520, which is aimed at lowering pathological tau and alpha-synuclein aggregates, key drivers of neurodegeneration in Alzheimer’s and Parkinson’s diseases. Both candidates reflect the company’s strategy of targeting multiple disease pathways with a single therapeutic approach. Annovis Bio conducts its clinical trials in North America and Europe, collaborating with academic research centers and contract research organizations to explore safety, pharmacodynamics and biomarker endpoints. The company’s leadership team brings together expertise in neurology, medicinal chemistry and drug development, with a commitment to translating early-stage research into viable treatments. As a publicly traded entity, Annovis continues to engage with scientific and investor communities to advance its programs toward potential regulatory approval.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24AMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off?Plugging In: How Kinder Morgan Powers Up ProfitsTSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
